Table of Contents Author Guidelines Submit a Manuscript
Journal of Diabetes Research
Volume 2013, Article ID 489869, 8 pages
http://dx.doi.org/10.1155/2013/489869
Clinical Study

Advanced Diabetic Nephropathy with Nephrotic Range Proteinuria: A Pilot Study of the Long-Term Efficacy of Subcutaneous ACTH Gel on Proteinuria, Progression of CKD, and Urinary Levels of VEGF and MCP-1

1Internal Medicine/Nephrology, University of Tennessee College Medicine, Chattanooga, TN 37403, USA
2Southeast Renal Research Institute, 45 East Main Street, Chattanooga, TN 37408, USA
3Renal Division, Ohio State University Wexner Medical Center, Columbus, OH 43210, USA

Received 21 April 2013; Revised 9 June 2013; Accepted 10 June 2013

Academic Editor: Giuseppe Paolisso

Copyright © 2013 J. A. Tumlin et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. I. H. De Boer, T. C. Rue, P. A. Cleary et al., “Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria: an analysis of the diabetes control and complications trial/epidemiology of diabetes interventions and complications cohort,” Archives of Internal Medicine, vol. 171, no. 5, pp. 412–420, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. R. O. Bonow and M. Gheorghiade, “The diabetes epidemic: a national and global crisis,” The American Journal of Medicine, vol. 116, no. 5, 2004. View at Publisher · View at Google Scholar · View at Scopus
  3. USRDS, “The United States Renal Data System,” The American Journal of Kidney Diseases, vol. 42, supplement 1, pp. 1–230, 2003. View at Google Scholar
  4. A. Jaureguia, D. Mintz, P. Mundela, and A. Fornonia, “Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and Microalbuminuria,” Current Opinion in Nephrology and Hypertension, vol. 18, pp. 539–545, 2009. View at Google Scholar
  5. T. W. Meyer, P. H. Bennett, and R. G. Nelson, “Podocyte number predicts long-term urinary albumin excretion in Pima Indians with Type II diabetes and microalbuminuria,” Diabetologia, vol. 42, no. 11, pp. 1341–1344, 1999. View at Publisher · View at Google Scholar · View at Scopus
  6. E. N. Ellis, M. W. Steffes, B. Chavers, and S. M. Mauer, “Observations of glomerular epithelial cell structure in patients with type I diabetes mellitus,” Kidney International, vol. 32, no. 5, pp. 736–741, 1987. View at Google Scholar · View at Scopus
  7. U. B. Berg, T. B. Torbjörnsdotter, G. Jaremko, and B. Thalme, “Kidney morphological changes in relation to long-term renal function and metabolic control in adolescents with IDDM,” Diabetologia, vol. 41, no. 9, pp. 1047–1056, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. N. J. Brown, S. Nakamura, L. Ma et al., “Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo,” Kidney International, vol. 58, no. 3, pp. 1219–1227, 2000. View at Publisher · View at Google Scholar · View at Scopus
  9. M.-L. Gross, A. El-Shakmak, A. Szábó et al., “ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy,” Diabetologia, vol. 46, no. 6, pp. 856–868, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. G. Wolf, S. Chen, and F. N. Ziyadeh, “From the periphery of the glomerular capillary wall toward the center of disease: podocyte injury comes of age in diabetic nephropathy,” Diabetes, vol. 54, no. 6, pp. 1626–1634, 2005. View at Publisher · View at Google Scholar · View at Scopus
  11. M. E. Pagtalunan, P. L. Miller, S. Jumping-Eagle et al., “Podocyte loss and progressive glomerular injury in type II diabetes,” Journal of Clinical Investigation, vol. 99, no. 2, pp. 342–348, 1997. View at Google Scholar · View at Scopus
  12. D. T. Wu, M. Bitzer, W. Ju, P. Mundel, and E. P. Böttinger, “TGF-β concentration specifies differential signaling profiles of growth arrest/differentiation and apoptosis in podocytes,” Journal of the American Society of Nephrology, vol. 16, no. 11, pp. 3211–3221, 2005. View at Publisher · View at Google Scholar · View at Scopus
  13. M. S. Pepper, J.-D. Vassalli, L. Orci, and R. Montesano, “Biphasic effect of transforming growth factor-β1 on in vitro angiogenesis,” Experimental Cell Research, vol. 204, no. 2, pp. 356–363, 1993. View at Publisher · View at Google Scholar · View at Scopus
  14. M. W. Steffes, J. D. Leffert, and J. M. Basgen, “Epithelial cell foot process width in intact and uninephrectomized diabetic and nondiabetic rats,” Laboratory Investigation, vol. 43, no. 3, pp. 225–230, 1980. View at Google Scholar · View at Scopus
  15. M. W. Steffes, D. Schmidt, R. McCrery et al., “Glomerular cell number in normal subjects and in type 1 diabetic patients,” Kidney International, vol. 59, no. 6, pp. 2104–2113, 2001. View at Publisher · View at Google Scholar · View at Scopus
  16. D. R. C. Dae Ryong Cha, N. H. K. Nan Hee Kim, J. W. Y. Jong Woo Yoon et al., “Role of vascular endothelial growth factor in diabetic nephropathy,” Kidney International, no. 77, pp. S104–S112, 2000. View at Google Scholar · View at Scopus
  17. E. Bailey, M. J. Bottomley, S. Westwell et al., “Vascular endothelial growth factor mRNA expression in minimal change, membranous, and diabetic nephropathy demonstrated by non-isotopic in situ hybridisation,” Journal of Clinical Pathology, vol. 52, no. 10, pp. 735–738, 1999. View at Google Scholar · View at Scopus
  18. B. Hohenstein, B. Hausknecht, K. Boehmer, R. Riess, R. A. Brekken, and C. P. M. Hugo, “Local VEGF activity but not VEGF expression is tightly regulated during diabetic nephropathy in man,” Kidney International, vol. 69, no. 9, pp. 1654–1661, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. H. J. Baelde, M. Eikmans, D. W. P. Lappin et al., “Reduction of VEGF-A and CTGF expression in diabetic nephropathy is associated with podocyte loss,” Kidney International, vol. 71, no. 7, pp. 637–645, 2007. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Müller-Deile, K. Worthmann, M. Saleem, I. Tossidou, H. Haller, and M. Schiffer, “The balance of autocrine VEGF-A and VEGF-C determines podocyte survival,” The American Journal of Physiology, vol. 297, no. 6, pp. F1656–F1667, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Ponticelli, P. Passerini, M. Salvadori et al., “A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy,” The American Journal of Kidney Diseases, vol. 47, no. 2, pp. 233–240, 2006. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Gong, “The renaissance of corticotropin therapy in proteinuric nephropathies,” Nature Reviews Nephrology, vol. 8, no. 2, pp. 122–128, 2012. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Lindskog, K. Ebefors, M. E. Johansson et al., “Melanocortin 1 receptor agonists reduce proteinuria,” Journal of the American Society of Nephrology, vol. 21, no. 8, pp. 1290–1298, 2010. View at Publisher · View at Google Scholar · View at Scopus
  24. B. Amann, R. Tinzmann, and B. Angelkort, “ACE inhibitors improve diabetic nephropathy through suppression of renal MCP-1,” Diabetes Care, vol. 26, no. 8, pp. 2421–2425, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. P. E. Pergola, P. Raskin, R. D. Toto et al., “Bardoxolone methyl and kidney function in CKD with type 2 diabetes,” The New England Journal of Medicine, vol. 365, no. 4, pp. 327–336, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. K. E. White, R. W. Bilous, S. M. Marshall et al., “Podocyte number in normotensive type 1 diabetic patients with albuminuria,” Diabetes, vol. 51, no. 10, pp. 3083–3089, 2002. View at Google Scholar · View at Scopus
  27. M. Zaidi, L. Suna, B. . Robinson, I. Tourkovab, L. Liub, Y. Wang et al., “ACTH protects against glucocorticoid-induced osteonecrosis of bone,” Proceedings of the National Academy of Sciences, vol. 107, pp. 8782–8787, 2012. View at Google Scholar
  28. A.-L. Berg and M. Arnadottir, “ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses,” Nephrology Dialysis Transplantation, vol. 19, no. 5, pp. 1305–1307, 2004. View at Publisher · View at Google Scholar · View at Scopus
  29. E. B. Farnsworth, “Studies on the influence of adrenocorticotropin in acute nephritis in simple nephrosis and in nephrosis with azotemia,” in Proceedings of the 1st Clinical ACTH Congress, pp. 297–317, 1950.
  30. C. Mallet, O. Féraud, G. Ouengue-Mbélé et al., “Differential expression of VEGF receptors in adrenal atrophy induced by dexamethasone: a protective role of ACTH,” The American Journal of Physiology, vol. 284, no. 1, pp. E156–E167, 2003. View at Google Scholar · View at Scopus
  31. J. L. Shifren, S. Mesiano, R. N. Taylor, N. Ferrara, and R. B. Jaffe, “Corticotropin regulates vascular endothelial growth factor expression in human fetal adrenal cortical cells,” Journal of Clinical Endocrinology and Metabolism, vol. 83, no. 4, pp. 1342–1347, 1998. View at Publisher · View at Google Scholar · View at Scopus